Â鶹tv

Aix-Â鶹tv (AMU) follows CNIL guidelines

The platform that broadcasts this content conditions its reading to the deposit of tracers in order to offer you targeted advertising according to your navigation.

By clicking on 'I authorize', the cookies will be deposited and you will be able to view this content.

I authorize

The Context

Cardiovascular pathologies, and in particular myocardial infarction (MI), are the leading cause of death in patients with chronic kidney disease (CKD). However, these patients are under-represented in large randomized clinical trials. Antithrombotic therapies, the cornerstone of IDM management, do a poor job of protecting these patients from the risk of recurrence. In addition, these treatments expose them to a significant risk of bleeding. In this context, the personalisation of antithrombotic treatment according to the individual risk of thrombosis and bleeding is a major issue.

The Project

The INNOV-CKD project, led by Professor Laurent Bonello, cardiologist at the APHM, aims to provide clinicians with blood tests that will make it possible to personalize antithrombotic treatment, to improve the survival and quality of life of patients while reducing healthcare costs.

Acute Coronary Syndrome (ACS)

Acute Coronary Syndrome (ACS) is a condition caused by a clot - or thrombus - in one or more of the arteries that supply blood to the heart and causes a myocardial infarction. This pathology affects 100,000 people in France and 800,000 in the United States each year. In 20 to 40% of cases, it concerns patients with chronic kidney disease (CKD).

The aim of the INNOV-CKD project

The objective of RHU INNOV-CKD is to develop and validate, after two clinical studies, innovative, automated methods that can be used in clinical practice to predict the individual risk of thrombosis and hemorrhage in CKD patients. Two innovative complementary tests targeting platelets and vascular endothelium will be developed to assess vascular integrity and measure the risk of thrombosis and hemorrhage in CKD patients. The ultimate goal is to automate and validate them in two clinical studies prior to their use by healthcare professionals.

Recognized scientific expertise

The result of a collaboration between recognized experts in vascular biology, nephrology and cardiology and leading manufacturers of innovative hemostasis tests, this project joins the two RHU projects already launched in Marseille: PIONEER (Pr Fabrice BARLESI) and EPINOV (Pr Fabrice BARTOLOMEI). This is a fine recognition of the excellence and dynamism of Marseille's clinical research teams.

Project management

Coordinated by Professor Laurent Bonello, the RHU INNOV-CKD is run annually by the partners of L'Idex Aix-Marseille: Aix-Â鶹tv (AMU), Assistance Publique Hôpitaux de Marseille (AP-HM), CNRS, Inserm, IRD, CEA, Sciences-Po Aix and Centrale Marseille.

Expected benefits

In the long term, the expected benefits are at the level of practitioners, patients and the socio-economic level. They are part of the development of "personalized medicine with a vascular focus".

• On the practitioners' side, it will become possible to determine the best preventive strategy and duration of treatment according to the best benefit-risk profile of the patient.
• On the patients' side, medical complications will be reduced in the short and long term, positively impacting their comfort and life expectancy.

The effective management of at-risk and hospitalized patients, which represents a high economic burden on health care systems, will have a significant impact on health costs and medico-economic gain.